JPH08198749A - Fat infusion preparation for diabetic use - Google Patents
Fat infusion preparation for diabetic useInfo
- Publication number
- JPH08198749A JPH08198749A JP3156195A JP3156195A JPH08198749A JP H08198749 A JPH08198749 A JP H08198749A JP 3156195 A JP3156195 A JP 3156195A JP 3156195 A JP3156195 A JP 3156195A JP H08198749 A JPH08198749 A JP H08198749A
- Authority
- JP
- Japan
- Prior art keywords
- fat
- acid
- oil
- transfusion
- linolenic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
【０００１】[0001]
【産業上の利用分野】本発明は、新規な糖尿病患者用の
静注用脂肪輸液剤に関するものである。TECHNICAL FIELD The present invention relates to a novel intravenous fat transfusion for diabetic patients.
【０００２】[0002]
【従来の技術】糖尿病時には糖の利用性が低下するた
め、エネルギー源として脂肪の適用が考えられる。従
来、経静脈栄養において必須脂肪酸およびエネルギー補
給にはｎ−６系必須脂肪酸であるリノール酸を多量に含
有する植物油が用いられている。前記植物油のひとつと
してダイズ油乳剤が挙げられるが、その主な構成脂肪酸
であるリノール酸のエネルギー産生効率に比べ、α−リ
ノレン酸のそれは明らかに高いことが知られている。と
ころが、α−リノレン酸を主成分とする脂肪輸液剤は未
だ広く利用されるに至っていない。2. Description of the Related Art Since the availability of sugar decreases during diabetes, the application of fat as an energy source is considered. Conventionally, vegetable oil containing a large amount of linoleic acid, which is an n-6 essential fatty acid, has been used for supplementing essential fatty acids and energy in parenteral nutrition. Soybean oil emulsion is mentioned as one of the vegetable oils, and it is known that that of α-linolenic acid is obviously higher than the energy production efficiency of linoleic acid, which is the main constituent fatty acid. However, fat transfusions containing α-linolenic acid as a main component have not been widely used yet.
【０００３】他方、糖尿病においては血管障害が多発
し、その発症および進展に血栓形成が重要な因子となっ
ている。トロンボキサンＡ2は強力な血小板凝集作用お
よび血管収縮作用を有しており、トロンボキサンＡ2産
生が亢進した状態になれば血栓が形成されやすくなる。
糖尿病ではアラキドン酸からのトロンボキサンＡ2産生
が亢進しており、アラキドン酸の前駆体であるリノール
酸を多量に含む油脂の投与には疑問がもたれる。一方、
ｎ−３系脂肪酸であるα−リノレン酸はリノール酸代謝
に拮抗しアラキドン酸の生成を抑制するのみでなく、ア
ラキドン酸からのエイコサノイドの産生も抑制すること
が知られている。On the other hand, in diabetes, vascular disorders frequently occur, and thrombus formation is an important factor for the onset and progress thereof. Thromboxane A 2 has a strong platelet aggregation action and vasoconstriction action, and a thrombus is likely to be formed if thromboxane A 2 production is enhanced.
In diabetes, thromboxane A 2 production from arachidonic acid is enhanced, and administration of oils and fats containing a large amount of linoleic acid, which is a precursor of arachidonic acid, is questionable. on the other hand,
It is known that α-linolenic acid, which is an n-3 fatty acid, not only antagonizes linoleic acid metabolism and suppresses the production of arachidonic acid, but also suppresses the production of eicosanoids from arachidonic acid.
【０００４】これまでｎ−３系脂肪酸の糖尿病に対する
効果は、主に魚油あるいは魚油濃縮物を経口投与して検
討されている。糖利用能を上昇させるとの報告（Popp-S
nijders C. et al. Diab. Res., 4, 141-147, 1987、St
orlien, L.H. et al. Science, 237, 885-887, 1987）
がある一方、耐糖能を悪化させるとの報告（Kasim S.E.
et al. J. Clin. Endcrinol. Metab., 67, 1-5, 198
8、Borkman M. et al. Diabetes, 38, 1314-1319, 198
9.、Friday K.E. et al. Diabetes Care, 12, 276-281,
1989）もあり、一定の見解が得られていない。これは
魚油にはｎ−３系脂肪酸とともに飽和およびモノ不飽和
脂肪酸も多く含まれることが、効果の判定をあいまいに
していると考えられる。一方、純粋なエイコサペンタエ
ン酸を経口投与した場合には、耐糖能の悪化を認めない
（角 誠二郎ほか, Ther. Res., 13,358-367, 1992）こ
とや、ドコサヘキサエン酸のエマルジョンは血糖値を低
下させる（Hamazaki, T. et al. Ann. N. Y. Acad. Sc
i., 683, 207-212, 1993）などの報告がある。また特開
昭60-248610号公報によれば、ｎ−３系多価不飽和脂肪
酸を含む油脂、例えば魚油またはそのエステルの経口投
与は、糖尿病時の赤血球膜流動性を増し合併症の予防あ
るいは治療に有効である旨が記載されているが、栄養改
善については確認されていない。Up to now, the effect of n-3 fatty acids on diabetes has been mainly studied by orally administering fish oil or fish oil concentrate. Reported to increase sugar utilization (Popp-S
nijders C. et al. Diab. Res., 4, 141-147, 1987, St
orlien, LH et al. Science, 237, 885-887, 1987)
However, it is reported that glucose tolerance deteriorates (Kasim SE
et al. J. Clin. Endcrinol. Metab., 67, 1-5, 198
8, Borkman M. et al. Diabetes, 38, 1314-1319, 198
9., Friday KE et al. Diabetes Care, 12, 276-281,
1989), a certain opinion has not been obtained. It is considered that the fact that fish oil contains a large amount of saturated and monounsaturated fatty acids as well as n-3 fatty acids makes the determination of the effect ambiguous. On the other hand, when pure eicosapentaenoic acid was orally administered, no deterioration in glucose tolerance was observed (Seijiro Kaku et al., Ther. Res., 13,358-367, 1992), and an emulsion of docosahexaenoic acid decreased blood glucose level. Let (Hamazaki, T. et al. Ann. NY Acad. Sc
i., 683, 207-212, 1993). Further, according to JP-A-60-248610, oral administration of an oil / fat containing an n-3 polyunsaturated fatty acid, for example, fish oil or its ester increases erythrocyte membrane fluidity in diabetes and prevents complications. Although it is described as effective for treatment, nutritional improvement has not been confirmed.
【０００５】また脂肪分中のα−リノレン酸エチルエス
テルあるいはトリグリセリド含量を１０〜５０％とした
脂肪輸液剤（特公平4-21645号公報）やα−リノレン酸
含有精製植物油（シソ油、エゴマ油あるいはアマニ油）
と大豆油を重量比で１：４〜４：１に混合した脂肪輸液
剤（特開平4-342534号公報）、精製エゴマ油を素材とし
た脂肪輸液（特開平5-39217号公報）が提案されてい
る。しかし、これらの脂肪輸液剤の糖尿病時の効果につ
いては確認されていない。Further, a fat transfusion agent (Japanese Patent Publication No. 4-21645) in which the content of α-linolenic acid ethyl ester or triglyceride in fat is 10 to 50%, and refined vegetable oil containing α-linolenic acid (Perilla oil, perilla oil) Or linseed oil)
And a soybean oil are mixed in a weight ratio of 1: 4 to 4: 1 to provide a fat transfusion agent (JP-A-4-342534) and a fat infusion solution using refined perilla oil (JP-A-5-39217). Has been done. However, the effect of these fat transfusions in diabetes has not been confirmed.
【０００６】[0006]
【発明が解決しようとする課題】従来のリノール酸含量
の多い脂肪輸液およびα−リノレン酸含有精製植物油を
配合した脂肪輸液剤はいずれも栄養補給を主たる目的と
したものである。また特公平4-21645号公報によればα
−リノレン酸を高濃度に含む脂肪輸液剤は抗血栓性製剤
としても有用であると示されているが、糖尿病時におけ
る栄養補給、脂肪酸代謝の異常およびエイコサノイド産
生異常の改善については検討されていない。The conventional fat transfusions containing a large amount of linoleic acid and a conventional refined vegetable oil containing α-linolenic acid are mainly intended for nutritional supplementation. According to Japanese Patent Publication No. 4-21645, α
-Fat infusion containing high concentration of linolenic acid has been shown to be useful as an antithrombotic drug, but no studies have been conducted on improvement of nutritional supplementation, abnormal fatty acid metabolism and abnormal eicosanoid production during diabetes. .
【０００７】従って本発明は、糖尿病時における脂肪酸
代謝の異常および病態を生理的代謝を介して改善し、ま
た必須脂肪酸を補給しつつエネルギー素材として良好な
糖尿病患者用の脂肪輸液剤を提供することにある。[0007] Therefore, the present invention provides a fat transfusion for diabetic patients, which improves abnormalities and pathological conditions of fatty acid metabolism during diabetes through physiological metabolism and which is a good energy material while supplementing essential fatty acids. It is in.
【０００８】[0008]
【課題を解決するための手段】本発明者らは糖尿病にお
ける脂肪酸代謝の変動および病態像の軽減について研究
を重ねた結果、α−リノレン酸を高濃度含有する脂肪輸
液が糖尿病時の脂肪酸代謝の改善を介してエイコサノイ
ド産生を良好に保ち、栄養状態を良好にせしめること、
またその効果は油脂成分としてα−リノレン酸を多く含
有する精製エゴマ油でなければ発現しないことを見い出
し、これに基づいて本発明を完成した。Means for Solving the Problems As a result of repeated studies on changes in fatty acid metabolism and diminution of pathological conditions in diabetes, the present inventors have found that a fat transfusion containing a high concentration of α-linolenic acid can improve fatty acid metabolism during diabetes. Maintaining good eicosanoid production through improvement and improving nutritional status,
Further, it was found that the effect was not exhibited unless the refined perilla oil contained a large amount of α-linolenic acid as an oil and fat component, and based on this, the present invention was completed.
【０００９】すなわち、本発明は油脂の構成脂肪酸であ
るリノール酸とα−リノレン酸について、遊離酸として
計算したリノール酸に対するα−リノレン酸の重量比が
２.５〜７.０である油脂を有効成分として含有する糖尿
病患者用脂肪輸液剤であり、その好ましい実施態様とし
ては、前記有効成分として、少なくとも精製エゴマ油を
含んでなる油脂を、脂肪輸液剤中に５〜３０ｗ／ｖ％含
有する糖尿病患者用脂肪輸液剤が挙げられる。That is, according to the present invention, for linoleic acid and α-linolenic acid, which are the constituent fatty acids of fats and oils, an oil and fat having a weight ratio of α-linolenic acid to linoleic acid calculated as a free acid of 2.5 to 7.0 is used. It is a fat transfusion for diabetic patients which is contained as an active ingredient, and in a preferred embodiment thereof, fats and oils containing at least purified perilla oil are contained in the fat transfusion as 5 to 30 w / v% as the active ingredient. A fat transfusion for diabetic patients can be mentioned.
【００１０】本発明の糖尿病用脂肪輸液剤に配合する油
脂としては、精製エゴマ油および精製エゴマ油と各種の
植物油を公知の方法で精製した精製植物油を混合したも
のが挙げられる。前記油脂は、その構成脂肪酸として、
リノール酸含量に対するα−リノレン酸含量の遊離酸と
して計算された重量比が１：２.５〜１：７.０、好まし
くは１：３.５〜１：５.５、より好ましくは１：４.０
〜１：５.０になるよう調製して配合することができ
る。なお、前記精製エゴマ油としては、精製エゴマ油を
加水分解反応に付して脂肪酸を遊離せしめた場合に、遊
離酸として計算されたα−リノレン酸の全遊離酸中に占
める割合が５１〜７０重量％であるものが好適に使用で
きる。Examples of fats and oils to be added to the fat transfusion for diabetes of the present invention include refined perilla oil and refined perilla oil mixed with refined vegetable oil obtained by purifying various vegetable oils by a known method. The oil and fat, as its constituent fatty acid,
The weight ratio of α-linolenic acid content to linoleic acid content, calculated as free acid, is 1: 2.5 to 1: 7.0, preferably 1: 3.5 to 1: 5.5, more preferably 1 :. 4.0
It can be prepared and blended so that it becomes ˜1: 5.0. As the purified perilla oil, when the purified perilla oil is subjected to a hydrolysis reaction to liberate a fatty acid, the ratio of α-linolenic acid calculated as the free acid in the total free acid is 51 to 70. Those that are in weight% can be preferably used.
【００１１】また、本発明の糖尿病患者用脂肪輸液剤に
は、従来より用いられている卵黄レシチンや水添大豆レ
シチン等の乳化剤、グリセリン、トコフェロール、また
必要に応じて安定剤や等張化剤等の添加剤を加えること
ができる。本発明の脂肪輸液剤に配合される精製エゴマ
油は、天然エゴマ油から得られる原油を脱ガム、脱酸、
脱色、脱臭、脱ロウおよび活性炭処理工程からなるスチ
ーム精製法により精製されたものを用いるとよい。前記
精製は、天然のエゴマ油に含まれる人体に対して毒性を
示す成分を除去するために行われるものである。さら
に、前記精製エゴマ油は、トコフェロール含有量が３１
〜２００ｍｇ/１００ｇになるようにトコフェロールを
添加したものが好適に使用できる。前記トコフェロール
含有量の調製は、精製エゴマ油の経時的な安定性を高め
るために行われ、更に脂肪輸液剤として投与された精製
エゴマ油から生じる過酸化物を低減させるために行われ
るものである。Further, the fat transfusion for diabetics of the present invention includes emulsifiers such as egg yolk lecithin and hydrogenated soybean lecithin which have been conventionally used, glycerin, tocopherol and, if necessary, stabilizers and isotonic agents. Additives such as Refined perilla oil blended in the fat transfusion of the present invention is a degumming, deoxidation of crude oil obtained from natural perilla oil,
What was refine | purified by the steam refining method which consists of decolorization, deodorization, dewaxing, and an activated carbon treatment process may be used. The refining is carried out in order to remove components that are toxic to the human body and are contained in natural perilla oil. Furthermore, the refined perilla oil has a tocopherol content of 31.
The thing which added tocopherol so that it might be set to -200 mg / 100g can be used conveniently. The tocopherol content is adjusted to increase the stability of refined perilla oil over time, and to reduce the peroxide generated from refined perilla oil administered as a fat transfusion. .
【００１２】本発明の糖尿病患者用脂肪輸液剤は、製造
される脂肪輸液剤１００容量部に対し精製エゴマ油をは
じめとする植物油を５〜３０重量％、好ましくは１０〜
２０重量％含有させ、精製卵黄レシチンまたは水添ダイ
ズレシチン１〜２重量％、グリセリン１.５〜３重量％
を配合して公知の脂肪輸液剤の製造法により製造するこ
とができる。The fat transfusion for diabetic patients of the present invention is 5 to 30% by weight, preferably 10 to 10% by volume of vegetable oil such as refined perilla oil with respect to 100 parts by volume of the fat transfusion prepared.
20% by weight, purified egg yolk lecithin or hydrogenated soybean lecithin 1-2% by weight, glycerin 1.5-3% by weight
It can be manufactured by a known method for manufacturing a fat transfusion.
【００１３】[0013]
実施例１ 精製エゴマ油１００ｇ（α−リノレン酸５５.６ｇ、リ
ノール酸１２.０ｇ含有、リノール酸に対するα−リノ
レン酸の重量比（比率）４.６）に卵黄レシチン６.０
ｇ、グリセリン１２.５ｇを加え、加温しながら激しく
攪拌して溶解後、適当量の注射用蒸留水を加えてホモジ
ナイザーで攪拌し、粗乳化液を調整した。この粗乳化液
をさらにマイクロフルイダイザーＭ−１１０Ｙ型（マイ
クロフルイダイザー社製）により高圧乳化させた後、注
射用蒸留水を加えて全量を５００ｍｌとした。ここに得
られた輸液をプラスチック製バックに充填、窒素置換後
密栓した。これを高圧蒸気滅菌することにより、精製エ
ゴマ油を２０ｗ／ｖ％含有する糖尿病患者用脂肪輸液剤
を調製した。Example 1 100 g of refined perilla oil (containing 55.6 g of α-linolenic acid and 12.0 g of linoleic acid, and a weight ratio (ratio) of α-linolenic acid to linoleic acid of 4.6) of yolk lecithin 6.0
g and 12.5 g of glycerin were added, and the mixture was vigorously stirred while heating to dissolve it, and then an appropriate amount of distilled water for injection was added and stirred with a homogenizer to prepare a crude emulsion. This crude emulsion was further subjected to high pressure emulsification with a Microfluidizer M-110Y type (manufactured by Microfluidizer), and distilled water for injection was added to bring the total volume to 500 ml. The infusion solution obtained here was filled in a plastic bag, replaced with nitrogen, and sealed. This was subjected to high-pressure steam sterilization to prepare a fat transfusion for diabetic patients containing 20 w / v% of purified perilla oil.
【００１４】実施例２ 精製エゴマ油１２５ｇ（α−リノレン酸６９.５ｇ、リ
ノール酸１５.０ｇ含有、リノール酸とα−リノレン酸
の重量比１：４.６）に卵黄レシチン６.０ｇ，グリセリ
ン１２.５ｇを加え、実施例１と同様の操作にて精製エ
ゴマ油を２５ｗ／ｖ％含有する糖尿病患者用脂肪輸液剤
を調製した。Example 2 125 g of purified perilla oil (containing 69.5 g of α-linolenic acid and 15.0 g of linoleic acid, a weight ratio of linoleic acid to α-linolenic acid of 1: 4.6), 6.0 g of egg yolk lecithin and glycerin. 12.5 g was added, and a fat transfusion for diabetic patients containing 25 w / v% of purified perilla oil was prepared in the same manner as in Example 1.
【００１５】実施例３ 精製エゴマ油１５０ｇ（α−リノレン酸８３.４ｇ、リ
ノール酸１８.０ｇ含有、リノール酸とα−リノレン酸
の重量比１：４.６）に精製水添ダイズレシチン６.０
ｇ、グリセリン１２.５ｇを加え、実施例１と同様の操
作にて精製エゴマ油を３０ｗ／ｖ％含有する糖尿病患者
用脂肪輸液剤を調製した。Example 3 150 g of purified perilla oil (containing 83.4 g of α-linolenic acid and 18.0 g of linoleic acid, a weight ratio of linoleic acid to α-linolenic acid of 1: 4.6) and purified hydrogenated soybean lecithin 6. 0
g and glycerin 12.5 g were added, and a fat transfusion for diabetic patients containing 30 w / v% of purified perilla oil was prepared in the same manner as in Example 1.
【００１６】実施例４ 精製エゴマ油１００ｇ（α−リノレン酸５５.６ｇ、リ
ノール酸１２.０ｇ含有、リノール酸とα−リノレン酸
の重量比１：４.６）に卵黄レシチン１２.０ｇ、グリセ
リン２５.０ｇを加え、実施例１と同様の操作にて全量
１０００ｍｌ中に精製エゴマ油を１０ｗ／ｖ％含有する
糖尿病患者用脂肪輸液剤を調製した。Example 4 100 g of purified perilla oil (containing 55.6 g of α-linolenic acid and 12.0 g of linoleic acid, a weight ratio of linoleic acid to α-linolenic acid of 1: 4.6), 12.0 g of egg yolk lecithin and glycerin. 25.0 g was added, and a fat transfusion for diabetic patients containing 10 w / v% of purified perilla oil in a total amount of 1000 ml was prepared in the same manner as in Example 1.
【００１７】実施例５ 精製エゴマ油９７ｇと精製ダイズ油３ｇを配合した油脂
（α−リノレン酸５４.２ｇ、リノール酸１３.１ｇ含
有、リノール酸とα−リノレン酸の重量比１：４.１）
に卵黄レシチン１２.０ｇ、グリセリン２５.０ｇを加
え、実施例１と同様の操作にて全量１０００ｍｌ中に油
脂を１０ｗ／ｖ％含有する糖尿病患者用脂肪輸液剤を調
製した。Example 5 Oil / fat containing 97 g of purified perilla oil and 3 g of refined soybean oil (containing 54.2 g of α-linolenic acid and 13.1 g of linoleic acid, and a weight ratio of linoleic acid to α-linolenic acid of 1: 4.1). )
12.0 g of egg yolk lecithin and 25.0 g of glycerin were added, and a fat transfusion for diabetic patients containing 10 w / v% of oil / fat in a total amount of 1000 ml was prepared in the same manner as in Example 1.
【００１８】試験例 ６週齢のＳＤ系雄性ラットを用い糖尿病モデル（ストレ
プトゾトシンにより誘発したモデル）を作製し、１週間
後に中心静脈にカテーテルを留置した後、脂肪輸液剤と
等エネルギー量のブドウ糖液（対照１）、ダイズ油（油
脂１００ｇ中α−リノレン酸７.３ｇ、リノール酸５０.
２ｇ、比率０.１）を主成分とした脂肪輸液剤（対照
２）及び実施例１の脂肪輸液をそれぞれ投与した。な
お、各試験群のラットの匹数は８〜９匹とし、被検液投
与期間中は無脂肪食で飼育した。また参考のため健常ラ
ット（６匹）および糖尿病ラット（７匹）の自由摂餌群
を設けた。被検液を７日間投与した後、栄養効果、血清
リン脂質脂肪酸組成、血小板トロンボキサンＡ2産生量
を測定した。Test Example A 6-week-old male SD rat was used to prepare a diabetes model (a model induced by streptozotocin), and one week later, a catheter was placed in the central vein, and then a glucose solution having an energy equivalent to that of a fat transfusion was prepared. (Control 1), soybean oil (7.3 g of α-linolenic acid in 100 g of oil and fat, 50.
A fat transfusion agent (control 2) containing 2 g of a ratio of 0.1) as a main component and the fat transfusion solution of Example 1 were administered. The number of rats in each test group was 8 to 9, and the rats were fed a fat-free diet during the administration of the test liquid. For reference, a free-feeding group of healthy rats (6) and diabetic rats (7) was provided. After the test liquid was administered for 7 days, the nutritional effect, serum phospholipid fatty acid composition, and platelet thromboxane A 2 production amount were measured.
【００１９】表１および表２に示したごとく、体重増加
量及び累積窒素出納は本発明の糖尿病患者用脂肪輸液剤
において従来の脂肪輸液剤（対照２）に比較し明らかに
高い値を示した。また表３に示したごとく、肝および腎
機能指標に異常はみられなかった。すなわち、本発明の
脂肪輸液剤は糖尿病時の栄養状態を良好に維持すること
が明らかになった。As shown in Tables 1 and 2, the weight gain and the cumulative nitrogen balance were clearly higher in the fat transfusion for diabetic patients of the present invention than in the conventional fat transfusion (control 2). . Further, as shown in Table 3, no abnormality was found in the liver and renal function indexes. That is, it was revealed that the fat transfusion according to the present invention favorably maintains the nutritional state during diabetes.
【００２０】[0020]
【表１】 [Table 1]
【００２１】[0021]
【表２】 [Table 2]
【００２２】[0022]
【表３】 [Table 3]
【００２３】表４に示したごとく、血漿インスリン濃度
は本発明の糖尿病患者用脂肪輸液剤において従来の脂肪
輸液剤（対照２）に比較し高い値を示した。As shown in Table 4, the plasma insulin concentration in the fat transfusion preparation for diabetic patients of the present invention was higher than that in the conventional fat transfusion preparation (Control 2).
【００２４】[0024]
【表４】 [Table 4]
【００２５】表５および表６に示したごとく、本発明の
糖尿病患者用脂肪輸液剤は血清リン脂質のアラキドン酸
を低下させ、エイコサペンタエン酸を上昇させるととも
に血小板トロンボキサンＡ2産生量を低下させた。すな
わち、本発明の糖尿病患者用脂肪輸液剤は、糖尿病時の
脂肪酸代謝及びエイコサノイド産生を改善することが明
らかとなった。As shown in Tables 5 and 6, the fat transfusion for diabetic patients of the present invention lowers the serum phospholipid arachidonic acid, eicosapentaenoic acid, and platelet thromboxane A 2 production amount. It was That is, it was revealed that the fat transfusion for diabetic patients of the present invention improves fatty acid metabolism and eicosanoid production during diabetes.
【００２６】[0026]
【表５】 [Table 5]
【００２７】[0027]
【表６】 [Table 6]
【００２８】[0028]
【作用】本発明の糖尿病患者用脂肪輸液剤は、糖尿病に
おける生理的代謝を介して血栓性合併症を改善しうる。
また病態時の栄養状態を改善する作用を有する。この効
果は、従来のリノール酸の多い脂肪輸液剤、あるいはリ
ノール酸含有量の多い油脂と混合した脂肪輸液剤では認
められず、α−リノレン酸含有量の多い脂肪輸液剤での
み認められる。The lipid transfusion for diabetic patients of the present invention can improve thrombotic complications through physiological metabolism in diabetes.
It also has the effect of improving the nutritional status during pathology. This effect is not observed in a conventional fat transfusion containing a large amount of linoleic acid or a fat transfusion containing a fat or oil containing a large amount of linoleic acid, but only in a fat transfusion containing a large amount of α-linolenic acid.
【００２９】[0029]
【発明の効果】本発明は、α−リノレン酸を高濃度含有
する脂肪輸液剤であるため、高カロリー輸液療法あるい
は低脂肪経腸栄養療法を施行時において糖尿病の合併症
の予防および栄養状態の改善に対し優れた効果を期待す
ることができる。EFFECTS OF THE INVENTION Since the present invention is a fat transfusion containing a high concentration of α-linolenic acid, the prevention of diabetic complications and nutritional status during high calorie transfusion therapy or low fat enteral nutrition therapy An excellent effect on improvement can be expected.
Claims (2)
−リノレン酸について、遊離酸として計算したリノール
酸に対するα−リノレン酸の重量比が２.５〜７.０であ
る油脂を有効成分として含有することを特徴とする糖尿
病患者用脂肪輸液剤。1. Linoleic acid, which is a constituent fatty acid of fats and oils, and α
-Regarding linolenic acid, a fat transfusion agent for diabetic patients, which comprises as an active ingredient an oil or fat having a weight ratio of α-linolenic acid to linoleic acid calculated as a free acid of 2.5 to 7.0.
ゴマ油を含んでなる油脂を、脂肪輸液剤中に５〜３０ｗ
／ｖ％含有する請求項１記載の糖尿病患者用脂肪輸液
剤。2. A fat and / or oil containing at least purified perilla oil as the active ingredient in a fat infusion solution in an amount of 5 to 30 w.
The fat transfusion for diabetic patients according to claim 1, wherein the fat transfusion is contained in an amount of / v%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP03156195A JP3840670B2 (en) | 1995-01-27 | 1995-01-27 | Fat transfusion for diabetics |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP03156195A JP3840670B2 (en) | 1995-01-27 | 1995-01-27 | Fat transfusion for diabetics |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH08198749A true JPH08198749A (en) | 1996-08-06 |
| JP3840670B2 JP3840670B2 (en) | 2006-11-01 |
Family
ID=12334597
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP03156195A Expired - Fee Related JP3840670B2 (en) | 1995-01-27 | 1995-01-27 | Fat transfusion for diabetics |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP3840670B2 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005032539A1 (en) * | 2003-09-30 | 2005-04-14 | Bioplanta Arzneimittel Gmbh | Alpha-linolenic acid and alpha-linolenic acid-containing vegetable oils used for combating diabetes |
| US7601757B2 (en) | 2003-09-05 | 2009-10-13 | Abbott Laboratories | Lipid system and methods of use |
-
1995
- 1995-01-27 JP JP03156195A patent/JP3840670B2/en not_active Expired - Fee Related
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7601757B2 (en) | 2003-09-05 | 2009-10-13 | Abbott Laboratories | Lipid system and methods of use |
| US7759507B2 (en) | 2003-09-05 | 2010-07-20 | Abbott Laboratories | Lipid system and methods of use |
| WO2005032539A1 (en) * | 2003-09-30 | 2005-04-14 | Bioplanta Arzneimittel Gmbh | Alpha-linolenic acid and alpha-linolenic acid-containing vegetable oils used for combating diabetes |
Also Published As
| Publication number | Publication date |
|---|---|
| JP3840670B2 (en) | 2006-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5656667A (en) | Fatty acid composition | |
| US5589508A (en) | Use of an emulsion to prepare an intravensously administered medicament for treating skin diseases | |
| CN1267085C (en) | Modifying the fatty acid composition of cell membranes of organs and tissues | |
| JP3559039B2 (en) | Use of emulsions for preparing parenterally administered medicaments for the treatment of inflammatory diseases | |
| JPS59172416A (en) | Fat transfusion solution | |
| NL8104348A (en) | NEW LIPID COMPOSITIONS SUITABLE FOR APPLICATION IN DIET, RESPIRATORY AND THERAPEUTIC. | |
| EP0321128A1 (en) | Fatty acid compositions | |
| Behrman et al. | Blood lipid alterations in infants receiving intravenous fat-free alimentation | |
| CA2625640A1 (en) | Intravenous essential fatty acid emulsion | |
| JPH06511384A (en) | Nutrition for humans and animals | |
| CN101194919B (en) | Hippophae rhamnoides seed oil fatty milk injection and technique of preparing the same | |
| EP0437519A1 (en) | Triglycerides and nutritional composition comprising such triglycerides. | |
| JPH0761954B2 (en) | Cholesterol lowering or raising inhibitor | |
| EP0201159A2 (en) | Pharmaceutical and dietary compositions containing linolenic acids for the treatment of benign prostatic hypertrophy | |
| JP3840670B2 (en) | Fat transfusion for diabetics | |
| CN111743996A (en) | Oral emulsion for improving memory and senile dementia and preparation method thereof | |
| JP3132085B2 (en) | Fat emulsion | |
| EP0465550B1 (en) | Pharmaceutical lipid composition for parenteral nutrition | |
| US20070225370A1 (en) | Nutritional Compositions and Methods | |
| Herrera et al. | Emergence of new injectable lipid emulsions in the USA: guidance for pediatric clinicians | |
| JPH0848626A (en) | Fat infusion agent | |
| JPH0692848A (en) | Emulsion for treating diabetes | |
| JPH0615469B2 (en) | Fat infusion | |
| JPH0539217A (en) | Fat transfusion solution containing refined perilla oil blended therein | |
| CA1334002C (en) | Essential fatty acid compositions and methods for the modulation of prostaglandin levels in mammals |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Written amendment |
Effective date: 20050621 Free format text: JAPANESE INTERMEDIATE CODE: A821 |
|
| A711 | Notification of change in applicant |
Effective date: 20050621 Free format text: JAPANESE INTERMEDIATE CODE: A712 |
|
| A131 | Notification of reasons for refusal |
Effective date: 20060124 Free format text: JAPANESE INTERMEDIATE CODE: A131 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060322 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060418 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060613 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20060718 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20060731 |
|
| R150 | Certificate of patent (=grant) or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090818 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090818 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100818 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100818 Year of fee payment: 4 |
|
| LAPS | Cancellation because of no payment of annual fees |